Compare Davita Inc (DVA) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nano Dimension Ltd - ADR — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Nano Dimension Ltd - ADR trades at $1.49 (market cap $314.71M). The key difference: Davita Inc is far larger — about 47.4× Nano Dimension Ltd - ADR's market cap, and Davita Inc is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| DVA | NNDM | |
|---|---|---|
Market Cap | $14.92B | $314.71M |
Sector | Health | Technology |
52-Week High | $235.71 | $2.14 |
52-Week Low | $103.87 | $1.21 |
Enterprise Value | $27.47B | -$94.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Nano Dimension (NNDM) trades at $1.48, down 1.33% with a bearish technical signal. The company reported Q1 2026 revenue of $102.44M but a net loss of -$293.30M, reflecting a -286.72% margin. Cash burn remains high at -$101.28M from operations. Recent news highlights board disputes with shareholder Murchinson and a proposed merger with Infinite Epigenetics, creating uncertainty.
The outlook is challenged by persistent losses and negative cash flow, though the P/B of 0.64 suggests undervaluation. Risks include execution on strategic plans and shareholder activism. Analyst sentiment is cautious given the lack of profitability and ongoing corporate governance issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
